- Home
- SMLR vs KYTX Comparison
SMLR vs KYTX Comparison
Compare SMLR & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMLR
- KYTX
- Stock Information
- Founded
- SMLR 2007
- KYTX 2018
- Country
- SMLR United States
- KYTX United States
- Employees
- SMLR N/A
- KYTX N/A
- Industry
- SMLR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- KYTX
- Sector
- SMLR Health Care
- KYTX
- Exchange
- SMLR Nasdaq
- KYTX NYSE
- Market Cap
- SMLR 289.5M
- KYTX 242.1M
- IPO Year
- SMLR 2014
- KYTX 2024
- Fundamental
- Price
- SMLR $63.65
- KYTX $4.39
- Analyst Decision
- SMLR
- KYTX Buy
- Analyst Count
- SMLR 0
- KYTX 5
- Target Price
- SMLR N/A
- KYTX $23.20
- AVG Volume (30 Days)
- SMLR 837.2K
- KYTX 258.5K
- Earning Date
- SMLR 11-04-2024
- KYTX 11-13-2024
- Dividend Yield
- SMLR N/A
- KYTX N/A
- EPS Growth
- SMLR N/A
- KYTX N/A
- EPS
- SMLR 2.04
- KYTX N/A
- Revenue
- SMLR $58,938,000.00
- KYTX N/A
- Revenue This Year
- SMLR N/A
- KYTX N/A
- Revenue Next Year
- SMLR N/A
- KYTX N/A
- P/E Ratio
- SMLR $31.23
- KYTX N/A
- Revenue Growth
- SMLR N/A
- KYTX N/A
- 52 Week Low
- SMLR $20.88
- KYTX $3.92
- 52 Week High
- SMLR $76.98
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- SMLR 74.78
- KYTX 40.46
- Support Level
- SMLR $43.17
- KYTX $3.94
- Resistance Level
- SMLR $76.98
- KYTX $4.34
- Average True Range (ATR)
- SMLR 7.84
- KYTX 0.37
- MACD
- SMLR 2.07
- KYTX -0.08
- Stochastic Oscillator
- SMLR 70.80
- KYTX 27.73
About SMLR Semler Scientific Inc.
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.